Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 5
1994 7
1995 12
1996 16
1997 39
1998 41
1999 31
2000 35
2001 15
2002 22
2003 16
2004 12
2005 17
2006 14
2007 14
2008 19
2009 18
2010 37
2011 30
2012 20
2013 22
2014 14
2015 13
2016 12
2017 9
2018 8
2019 8
2020 9
2021 5
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

485 results
Results by year
Filters applied: . Clear all
Page 1
Sertindole for schizophrenia.
Lewis R, Bagnall A, Leitner M. Lewis R, et al. Cochrane Database Syst Rev. 2000;(2):CD001715. doi: 10.1002/14651858.CD001715. Cochrane Database Syst Rev. 2000. PMID: 10796657 Updated. Review.
Sertindole has therefore been withdrawn from the market pending discussion with the European Regulatory Authority over cardiac safety. ...REVIEWER'S CONCLUSIONS: Because of the cardiac problems, even evident within poorly reported studies, at present sertindole shou
Sertindole has therefore been withdrawn from the market pending discussion with the European Regulatory Authority over cardiac safety
Sertindole for schizophrenia.
Lewis R, Bagnall AM, Leitner M. Lewis R, et al. Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article. Review.
One was a medium term (eight weeks) placebo controlled study that examined three different doses of sertindole (8, 12 and 20mg/day). The remaining two studies compared the use of sertindole with haloperidol (10mg/day). One was a short term study (six weeks) that loo …
One was a medium term (eight weeks) placebo controlled study that examined three different doses of sertindole (8, 12 and 20mg/day). …
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Huhn M, et al. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Lancet. 2019. PMID: 31303314 Free PMC article.
Mean differences compared to placebo for weight gain (28 317 participants) ranged from -016 kg (-073 to 040; ziprasidone) to 321 kg (210 to 431; zotepine), for prolactin elevation (21 569 participants) from -7705 ng/mL (-12023 to -3354; clozapine) to 4851 ng/mL (4352 to 5351; pal …
Mean differences compared to placebo for weight gain (28 317 participants) ranged from -016 kg (-073 to 040; ziprasidone) to 321 kg (210 to …
Sertindole for the treatment of schizophrenia.
Azorin JM, Kaladjian A, Fakra E, Adida M. Azorin JM, et al. Expert Opin Pharmacother. 2010 Dec;11(18):3053-64. doi: 10.1517/14656566.2010.536217. Expert Opin Pharmacother. 2010. PMID: 21080854 Review.
Pivotal as well as supportive randomized controlled trials are reviewed along with observational and/or naturalistic safety studies. WHAT THE READER WILL GAIN: This review of sertindole will allow the reader to determine the place for sertindole in the schizophrenia …
Pivotal as well as supportive randomized controlled trials are reviewed along with observational and/or naturalistic safety studies. WHAT TH …
Sertindole in schizophrenia: efficacy and safety issues.
Muscatello MR, Bruno A, Micali Bellinghieri P, Pandolfo G, Zoccali RA. Muscatello MR, et al. Expert Opin Pharmacother. 2014 Sep;15(13):1943-53. doi: 10.1517/14656566.2014.947960. Epub 2014 Aug 1. Expert Opin Pharmacother. 2014. PMID: 25084209 Review.
EXPERT OPINION: The reviewed studies suggest a beneficial effect of sertindole on positive, negative and cognitive symptoms, and on relapse prevention. Although generally well tolerated, sertindole is associated with a dose-related QT-interval prolongation; thus, it …
EXPERT OPINION: The reviewed studies suggest a beneficial effect of sertindole on positive, negative and cognitive symptoms, and on r …
Sertindole: efficacy and safety in schizophrenia.
Lindström E, Levander S. Lindström E, et al. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. doi: 10.1517/14656566.7.13.1825. Expert Opin Pharmacother. 2006. PMID: 16925508 Review.
Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. ...For negative symptoms, one study obtained equivalent …
Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have …
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Leucht S, et al. Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27. Lancet. 2013. PMID: 23810019 Review.
The standardised mean differences with 95% credible intervals were: clozapine 088, 073-103; amisulpride 066, 053-078; olanzapine 059, 053-065; risperidone 056, 050-063; paliperidone 050, 039-060; zotepine 049, 031-066; haloperidol 045, 039-051; quetiapine 044, 035-052; aripiprazo …
The standardised mean differences with 95% credible intervals were: clozapine 088, 073-103; amisulpride 066, 053-078; olanzapine 059, 053-06 …
Sertindole : a review of its use in schizophrenia.
Murdoch D, Keating GM. Murdoch D, et al. CNS Drugs. 2006;20(3):233-55. doi: 10.2165/00023210-200620030-00005. CNS Drugs. 2006. PMID: 16529528 Review.
Extensive data from post-marketing studies do not indicate an excess of overall mortality with sertindole. Sertindole is at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. ...Thus, sertindole is a us …
Extensive data from post-marketing studies do not indicate an excess of overall mortality with sertindole. Sertindole is at le …
Efficacy and safety of sertindole in schizophrenia: a clinical review.
Zoccali RA, Bruno A, Muscatello MR. Zoccali RA, et al. J Clin Psychopharmacol. 2015 Jun;35(3):286-95. doi: 10.1097/JCP.0000000000000305. J Clin Psychopharmacol. 2015. PMID: 25830594 Review.
The pharmacological properties, clinical efficacy, safety, and tolerability of sertindole are covered in this article based on a literature review from 1990 to 2014. Given current available findings, sertindole is at least effective as haloperidol, risperidone, and …
The pharmacological properties, clinical efficacy, safety, and tolerability of sertindole are covered in this article based on a lite …
Sertindole versus other atypical antipsychotics for schizophrenia.
Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmidt F, Lewis R, Kissling W, Leucht S. Komossa K, et al. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006752. doi: 10.1002/14651858.CD006752.pub2. Cochrane Database Syst Rev. 2009. PMID: 19370652 Free PMC article. Review.
Compared with relatively high doses of risperidone (between 4 and 12 mg/day), sertindole produced significantly less akathisia and parkinsonism (1 RCT, n=321, RR 0.24 CI 0.09 to 0.69, NNT 14, CI 8 to 100). ...AUTHORS' CONCLUSIONS: Sertindole may induce fewer movemen …
Compared with relatively high doses of risperidone (between 4 and 12 mg/day), sertindole produced significantly less akathisia and pa …
485 results